002873 Guiyang Xintian Pharmaceutical
- 11.44
- +0.06+0.53%
Guiyang Xintian Pharmaceutical News
Xintian Pharmaceutical (002873.SZ): Net profit of 15.571,600 yuan in the first quarter decreased by 37.94% year-on-year
Gelonghui, April 26 | Xintian Pharmaceutical (002873.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 177 million yuan, down 15.06% year on year; net profit attributable to shareholders of listed companies was 15.571,600 yuan, down 37.94% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 147.152 million yuan, down 38.53% year on year; basic earnings per share were 0.0673 yuan.
Guiyang Xintian PharmaceuticalLtd (SZSE:002873) Sheds 14% This Week, as Yearly Returns Fall More in Line With Earnings Growth
It might be of some concern to shareholders to see the Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) share price down 22% in the last month. But that doesn't change the fact that the return
Xintian Pharmaceutical (002873.SZ): Strategically invested in Huilun Pharmaceutical, the current shareholding ratio is 14.88%
Gelonghui, April 17 | Xintian Pharmaceutical (002873.SZ) said on the investor interactive platform that the company's strategic investment in Huilun Pharmaceutical currently has a shareholding ratio of 14.88%. According to relevant accounting policy regulations, it has not yet been included in the scope of the company's consolidated statements, and changes in its operating performance will not have a significant impact on the company's 2023 net profit and other indicators. According to a thorough understanding of the business situation of Huilun Pharmaceutical Company, it is a high-tech enterprise dedicated to R&D and technical services for small molecule innovative drugs and generic drugs. The industrialization and commercialization process of its chemical products has been steady, and its business has grown rapidly in the past three years. 2
Xintian Pharmaceutical (002873.SZ) announced its 2023 annual results, net profit of 808.711 million yuan, a decrease of 27.48%
Xintian Pharmaceutical (002873.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
Xintian Pharmaceutical (002873.SZ): As of April 10, 2024, the number of shareholders in the company was 18,837
Gelonghui, April 11 | Xintian Pharmaceutical (002873.SZ) said on an interactive platform that as of April 10, 2024, the number of shareholders of the company was 18,837.
Xintian Pharmaceutical (002873.SZ) has spent 75.3 million yuan to buy back 8.806 million shares
Xintian Pharmaceutical (002873.SZ) issued an announcement. As of March 31, 2024, the company has approved share repurchases...
Market Might Still Lack Some Conviction On Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) Even After 45% Share Price Boost
Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) shares have had a really impressive month, gaining 45% after a shaky period beforehand. Not all shareholders will be feeling jubilant, since th
Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Most Bullish Insider, CEO Da Lun Dong Must Be Pleased With the Recent 21% Gain
Key Insights Significant insider control over Guiyang Xintian PharmaceuticalLtd implies vested interests in company growth The top 7 shareholders own 50% of the company 18% of Guiyang Xintian Pha
Gelonghui Announcement Selection | Huarong Chemical: Net profit increased by 13.53% to 139 million yuan in 2023, and plans to pay 10 to 2 yuan; Shanghai Industrial: Satellite components-related business and robot system integration business account for re
[Hot Focus] Shanghai Shanghai Industrial (603131.SH): The satellite component-related business and robot system integration business account for a relatively small share of the revenue. Currently, the company's main business has not changed. Shanghai Shanghaihang Satellite Technology Co., Ltd., a wholly-owned subsidiary of the company, is involved in some satellite component-related businesses, and its revenue accounts for about 1%-2% of the listed companies' revenue; the company is involved in robot system integration, and the revenue accounts for about 1%-2% of the listed company's revenue. 603131.SH Satellite component-related business and robot system integration business account for relatively small revenue
Xintian Pharmaceutical (002873.SZ): Trading of the company's shares and convertible bonds will resume on March 8
Gelonghui, March 7, 丨 Xintian Pharmaceutical (002873.SZ) announced that following the company's application to the Shenzhen Stock Exchange, trading of the company's shares and convertible corporate bonds will resume trading from the opening of the market on March 8, 2024 (Friday), and convertible corporate bonds will resume conversion on the same day.
Xintian Pharmaceutical (002873.SZ): Plans to purchase 85.12% of Huilun Pharmaceutical's shares
On March 7, Gelonghui | Xintian Pharmaceutical (002873.SZ) announced that it plans to purchase 85.12% of Huilun Pharmaceutical's shares held by 88 Huilun Pharmaceutical shareholders, including Dong Dalun, Dong Zhu, and Hainan Qianyao, through the issuance of shares. After the transaction is completed, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company. This transaction does not involve raising supporting funds. After the audit and evaluation work relating to the underlying asset is completed, the listed company will sign a supplementary agreement with the counterparty to issue shares and purchase assets, confirm the final transaction price and transaction plan, and disclose it in the restructuring report. What is Huilun Pharmaceutical's main business
Xintian Pharmaceutical (002873.SZ): 3.8037% of shares have been cumulatively repurchased
Gelonghui, March 1, 丨 Xintian Pharmaceutical (002873.SZ) announced that as of February 29, 2024, the company had repurchased a total of 8,806,030 shares through a special share repurchase account, accounting for 3.8037% of the company's total share capital of 231,514,155 shares on February 29, 2024. The maximum transaction price was 9.40 yuan/share, and the minimum transaction price was 7.67 yuan/share. The total amount paid was 75,303,968.97 yuan (including transaction fees).
Xintian Pharmaceutical (002873.SZ): Shuofang Pharmaceutical passed the high-tech enterprise certification
Gelonghui, Feb. 29丨Xintian Pharmaceutical (002873.SZ) announced that Shanghai Shuofang Pharmaceutical Technology Co., Ltd. (“Shuofang Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Shanghai Municipal Science and Technology Commission, the Shanghai Finance Bureau, and the Shanghai Taxation Bureau of the State Administration of Taxation, which has passed the certification of a high-tech enterprise.
Xintian Pharmaceutical (002873.SZ): Planning major asset restructuring matters and suspending trading tomorrow
Gelonghui, Feb. 22丨Xintian Pharmaceutical (002873.SZ) announced that the company is planning to issue shares to some shareholders of Shanghai Huilun Pharmaceutical Co., Ltd. (“Huilun Pharmaceutical”) to purchase part of Huilun Pharmaceutical's shares and control Huilun Pharmaceutical (hereinafter referred to as “this transaction”). Since matters related to this transaction are still in the planning stage, there is uncertainty. In order to protect the interests of investors, ensure the fairness of the company's information disclosure, and avoid abnormal fluctuations in the company's stock price, after applying to the Shenzhen Stock Exchange, the company's stock (stock abbreviation: Xintian Pharmaceutical, stock code: 002873
Xintian Pharmaceutical (002873.SZ): The repurchase was completed with a cumulative cost of 384.083 million yuan to repurchase 1.735% of the shares
Gelonghui, Feb. 2, 丨 Xintian Pharmaceutical (002873.SZ) announced that the actual repurchase range for this share repurchase plan is January 17, 2024 to February 2, 2024. As of February 2, 2024, the company has accumulated 4,017,200 shares of the company's shares through a dedicated share repurchase securities account through centralized bidding transactions, accounting for about 1.7352% of the company's total share capital. The highest transaction price was RMB 11.83 per share. The minimum transaction price was RMB 8.56 per share, and the total amount paid was RMB 384.083 million (including transaction fees). As of the date of this announcement, the company now
Xintian Pharmaceutical (002873.SZ): Accumulated cost of RMB 28.3826 million to repurchase 1.257% of shares
Gelonghui, February 1, 丨 Xintian Pharmaceutical (002873.SZ) announced that as of February 1, 2024, the company had repurchased 2,910,900 shares of the company's shares through a special stock repurchase account, accounting for 1.2573% of the company's total share capital of 231,514,155 shares on January 31, 2024. The maximum transaction price was 11.83 yuan/share, and the minimum transaction price was 9.08 yuan/share. The total amount paid was RMB 28.3826 million (including transaction fees).
Xintian Pharmaceutical (002873.SZ): The company's products account for about 67% of the company's revenue, and the OTC market contributes about 33% to revenue
Gelonghui, January 18 | Xintian Pharmaceutical (002873.SZ) said during a survey receiving institutional investors that from now on, in terms of sales channels, the company's products account for about 67% of the revenue on the hospital side, and the OTC market's contribution to revenue is about 33%. According to the company's market development strategy plan, it is expected that through continuous growth over the next 3-5 years, the hospital side market and OTC channel side will gradually form a 1:1 revenue contribution pattern, leading product revenue composition will be more reasonable and stable, and the second and third tier varieties will form a stable market foundation.
Xintian Pharmaceutical (002873.SZ): Currently, key R&D projects mainly cover modules such as innovative traditional Chinese medicine
Gelonghui, January 18 | Xintian Pharmaceutical (002873.SZ) said during a survey receiving institutional investors that the company's current key R&D projects mainly cover modules such as innovative traditional Chinese medicine drugs, traditional Chinese medicine formula granules, ancient classic recipes, and re-research on marketed products. The R&D focus has always focused on the fields of gynecology, urinary diseases, and chronic diseases with the company's rich marketing resources and strong product influence. 1. Innovative traditional Chinese medicine, ancient classic recipes: Multiple R&D projects focusing on dominant conditions are being promoted simultaneously. Both R&D modules have new product registration plans in 2024; 2. Traditional Chinese medicine distribution
Xintian Pharmaceutical (002873.SZ): Initial repurchase of 150,000 shares involving an investment of 1,7681 million yuan
Gelonghui, January 17, 丨 Xintian Pharmaceutical (002873.SZ) announced that on January 17, 2024, the company implemented a repurchase for the first time using centralized bidding transactions through a special stock repurchase account. The number of repurchases was 150,000 shares, accounting for 0.0648% of the company's total share capital. The highest transaction price was 11.83 yuan/share, the minimum transaction price was 11.74 yuan/share, and the total amount paid was 17.681 million yuan (including transaction fees).
Xintian Pharmaceutical (002873.SZ): As of January 10, 2024, the number of shareholders of the company was 20,936
Gelonghui January 17 | Xintian Pharmaceutical (002873.SZ) said on an interactive platform that as of January 10, 2024, the number of shareholders of the company was 20,936.
Analysis
Price Target
No Data
